The generation, maturation and remodelling of the extracellular matrix (ECM) are essential for the formation of alveoli during lung development. Alveoli formation is disturbed in preterm infants that develop bronchopulmonary dysplasia (BPD), where collagen fibres are malformed, and perturbations to lung ECM structures may underlie BPD pathogenesis. Malformed ECM structures might result from abnormal protein cross-linking, in part attributable to the increased expression and activity of transglutaminase 2 (TGM2) that have been noted in affected patient lungs, as well as in hyperoxia-based BPD animal models. The objective of the present study was to assess whether TGM2 plays a causal role in normal and aberrant lung alveolarization. Targeted deletion of Tgm2 in C57BL/6J mice increased septal thickness and reduced gas-exchange surface area in otherwise normally developing lungs. During aberrant lung alveolarization that occurred under hyperoxic conditions, collagen structures in Tgm2 À/À mice were partially protected from the impact of hyperoxia, where normal dihydroxylysinonorleucine and hydroxylysylpiridinoline collagen cross-link abundance was restored; however, the lung alveolar architecture remained abnormal. Inhibition of transglutaminases (including TGM2) with cysteamine appreciably reduced transglutaminase activity in vivo, as assessed by N e -(c-L-glutamyl)-L-lysine abundance and TGM catalytic activity, and restored normal dihydroxylysinonorleucine and hydroxylysylpiridinoline collagen cross-link abundance under pathological conditions. Furthermore, a moderate improvement in alveoli size and gas-exchange surface density was noted in cysteamine-treated mouse lungs in which BPD was modelled. These data indicate that TGM2 plays a role in normal lung alveolarization, Abbreviations BAPN, b-aminopropionitrile; BPD, bronchopulmonary dysplasia; CE, coefficient of error; CV, coefficient of variation; DHLNL, dihydroxylysinonorleucine; HLNL, hydroxylysinonorleucine; HP, hydroxylysylpiridinoline; MLI, mean linear intercept; P, postnatal day; TG2, transglutaminase 2; tTG, tissue transglutaminase.
The generation, maturation and remodelling of the extracellular matrix (ECM) are essential for the formation of alveoli during lung development. Alveoli formation is disturbed in preterm infants that develop bronchopulmonary dysplasia (BPD), where collagen fibres are malformed, and perturbations to lung ECM structures may underlie BPD pathogenesis. Malformed ECM structures might result from abnormal protein cross-linking, in part attributable to the increased expression and activity of transglutaminase 2 (TGM2) that have been noted in affected patient lungs, as well as in hyperoxia-based BPD animal models. The objective of the present study was to assess whether TGM2 plays a causal role in normal and aberrant lung alveolarization. Targeted deletion of Tgm2 in C57BL/6J mice increased septal thickness and reduced gas-exchange surface area in otherwise normally developing lungs. During aberrant lung alveolarization that occurred under hyperoxic conditions, collagen structures in Tgm2 À/À mice were partially protected from the impact of hyperoxia, where normal dihydroxylysinonorleucine and hydroxylysylpiridinoline collagen cross-link abundance was restored; however, the lung alveolar architecture remained abnormal. Inhibition of transglutaminases (including TGM2) with cysteamine appreciably reduced transglutaminase activity in vivo, as assessed by N e -(c-L-glutamyl)-L-lysine abundance and TGM catalytic activity, and restored normal dihydroxylysinonorleucine and hydroxylysylpiridinoline collagen cross-link abundance under pathological conditions. Furthermore, a moderate improvement in alveoli size and gas-exchange surface density was noted in cysteamine-treated mouse lungs in which BPD was modelled. These data indicate that TGM2 plays a role in normal lung alveolarization,
Introduction
Alveoli are the principle gas-exchange units of the lung. The molecular mechanisms that guide the formation of these alveoli remain poorly understood [1, 2] , but include transcription factor regulation, growth factor signalling and extracellular matrix (ECM) deposition and remodelling; all of which act in concert, together with physical forces such as in utero and postnatal breathing motions, to drive the formation of the lung structure [3, 4] . This process of alveolarization is disturbed in preterm infants with bronchopulmonary dysplasia (BPD). These infants had received oxygen supplementation to manage acute respiratory failure, and the oxygen toxicity and mechanical ventilation from this life-saving intervention stunt lung development. Affected lungs are, therefore, characterized by fewer, larger alveoli; and consequently, a reduced gasexchange surface area. This leads to short-and longterm consequences for the respiratory health of affected patients [5, 6] .
The pathomechanisms at play during aberrant lung alveolarization associated with BPD have not been fully clarified [1] . Studies on BPD pathogenesis rely on animal models where hyperoxia, used to mimic oxygen supplementation, generates a comparable histopathological picture in the lungs of developing mouse pups [7, 8] . The role of the ECM in both normal and aberrant lung alveolarization has received much attention, in both clinical and experimental BPD [4] . In these studies, the disordered structure of both elastin and collagen fibres, as well as other ECM components of the lung, has been noted. In particular, secondary collagen fibres in the developing parenchyma of human neonates with BPD have been described to be 'disorganized, tortuous and thickened' [9] , suggesting that pronounced perturbations to ECM structures accompany arrested alveolarization; however, collagen cross-links have not been studied. The post-translational processing and assembly of collagen fibres, and other ECM components, is a complex process, which also involves the cross-linking activity of members of the lysyl oxidase, lysyl hydroxylase and transglutaminase families [4] . These cross-linking systems are notable, since the expression and activity of members of all three families of protein cross-linking enzymes are altered in both experimental and clinical BPD [10] [11] [12] [13] [14] [15] [16] [17] [18] . While most of these studies are correlative, at least one study has documented that inhibition of lysyl oxidases using baminopropionitrile (BAPN) in experimental BPD in mice resulted in improved morphology of ECM structures, however, did not protect against the impact of hyperoxia on the alveolar architecture [15] .
Transglutaminases (EC 2.3.2.13) have also received attention as pathogenic mediators of lung diseases. Transglutaminases, first discovered by Heinrich Waelsch in 1957 [19] are Ca 2+ -dependent protein crosslinking enzymes, and are represented by seven members, named TGM1-TGM7; as well as the A subunit of factor XIII [20] . Additionally, a noncatalytic TGM homologue has been described: erythrocyte band 4.2, a cytoskeletal protein in red blood cells [20] . Catalytically active transglutaminases, which are described as 'nature's glues', covalently link polypeptides through the generation of an N e -(c-L-glutamyl)-L-lysine cross-link, and can act on multiple ECM substrates that include various collagens, as well as fibronectin [20] . Of these transglutaminases, TGM2 (also called TG2; or tissue transglutaminase, tTG) [21] [22] [23] has received particular attention as a pathogenic mediator of coeliac [24] and neurodegenerative [25] disease. TGM2 has also been implicated in lung diseases, including lung fibrosis [26, 27] , cystic fibrosis [28] , pulmonary hypertension [29] [30] [31] and airway inflammation [32, 33] . The observation that TGM2 expression changes over the course of lung alveolarization in rats [34, 35] is noteworthy, given that TGM2 lung steady-state mRNA and protein levels are increased in preterm infants that died with BPD [18] . Furthermore, steady-state Tgm2 mRNA and TGM2 protein levels were elevated in mouse lungs in experimental BPD, where increased N e -(c-L-glutamyl)-L-lysine cross-link immunoreactivity was also noted. These correlative studies suggested that TGM2 might play a pathogenic role in arrested alveolarization associated with BPD. To address this idea, the aim of this study was to assess a causal contribution for TGM2 in normal lung alveolarization, as well as arrested lung development associated with experimental BPD.
Results
Hyperoxia increases Tgm2 steady-state mRNA levels in developing mouse lungs
The steady-state mRNA levels of seven transglutaminases were assessed in lung tissue from wild-type mouse pups on postnatal day (P)14 that had been exposed to normoxia (21% O 2 ) or hyperoxia (85% O 2 ) for the first 14 days of postnatal life. The steady-state mRNA levels of six transglutaminases (with the exception of Tgm2) were also assessed in lung tissue from Tgm2 À/À mouse pups at P14. The genotype and phenotype of the Tgm2 À/À mice was first confirmed, where loss of exons 6-8 of the Tgm2 gene was verified in gDNA by PCR (Fig. 1A) , and loss of TGM2 protein in P14 Tgm2
À/À mouse pup lungs was documented by immunoblot (Fig. 1B) . The specificity of the anti-TGM2 antibody was validated by immunoblot (Fig. 2) . Additionally, no TGM2 immunoreactivity was detected in P14 Tgm2
À/À mouse pup lungs by immunohistochemistry (Fig. 1C) . The expression of all seven transglutaminases in P14 mouse pup lungs was noted, where, unexpectedly, appreciable steady-state mRNA levels of other transglutaminases were also detected. Hyperoxia exposure exhibited the most pronounced impact on steady-state Tgm2 mRNA levels. After 14 days of exposure to 85% O 2 , steady-state Tgm2 mRNA levels in mouse lungs were elevated 11-fold compared to 21% O 2 -exposed homozygous mouse pups (age: postnatal day 14) were resolved by reducing SDS/PAGE, and transferred to polyvinyldifluoride membranes, which were probed either with rabbit anti-mouse TGM2 (abcam, catalogue number ab109200; 1 : 5000), followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (ThermoFisher, catalogue number 31460; 1 : 3000) (left-hand panel), or with goat anti-mouse/ guinea pig TGM2 antibody (Millipore, 06-471; 1 : 5000) followed by horseradish peroxidase-conjugated rabbit anti-goat IgG (ThermoFisher, catalogue number 31402; 1 : 3000) (right-hand panel). In the case of the abcam antibody, loading equivalence was determined using b-actin, detected with a rabbit anti-mouse b-actin antibody (Cell Signaling Technology, catalogue number 4967; 1 : 1000), followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (ThermoFisher, catalogue number 31460; 1 : 3000). It was not deemed necessary to assess loading equivalence for the studies with the Millipore antibody. The arrowhead indicated the position of the TGM2 band at the correct molecular mass, while the asterisk (*) denotes a cross-reacting band. WT, wild-type; À/À, Tgm2
control mice (Fig. 3A,C) . In contrast, a smaller magnitude of change in steady-state mRNA levels was noted for Tgm3, Tgm4, Tgm5 and Tgm6, where all four transglutaminase family members exhibited decreased steady-state mRNA levels (Fig. 3A,C) . In the lungs of Tgm2 À/À mouse pups at P14, no increased expression of other transglutaminases was noted, however, a small decrease in steady-state Tgm5 mRNA levels was noted (Fig. 3B,C) . These data highlight Tgm2 expression as being upregulated by hyperoxia in the lungs of mice.
TGM2 partially mediates the impact of hyperoxia on collagen structure in developing mouse lungs
Exposure of newborn mouse pups to 85% O 2 for the first 2 weeks of postnatal life drove an apparent increase in the amount of collagen in the alveolar walls, as assessed by visual inspection of Sirius Red F 3B-stained lung tissue sections, compared to 21% O 2 -exposed control mice (Fig. 4A,B ). This pattern was also noted in the hyperoxia-versus normoxia-exposed Tgm2 À/À mice (Fig. 4C,D) . However, these data are qualitative at best. Additionally, 21% O 2 -exposed Tgm2 À/À mice appeared to have thickened alveolar walls ( Fig. 4C ) compared to 21% O 2 -exposed wildtype mice (Fig. 4A) .
To quantify the impact of the loss of TGM2 on collagen structures, the amount of collagen, and collagen cross-links was measured in lung tissues (Fig. 5) . As suggested by the images presented in Fig. 4 comparing 21% O 2 -exposed versus 85% O 2 -exposed wild-type mice (Fig. 5B) . Specifically, the abundance of the mature, trifunctional hydroxylysylpyridinoline (HP) cross-link was reduced in Tgm2 À/À mice in comparison to wild-type mice, in the background of hyperoxia (Fig. 5C ). This is consistent with the reduced abundance of the immature bifunctional dihydroxylysinonorleucine (DHLNL) cross-link ( Fig. 5D ), which displayed a similar pattern; since DHLNL serves as a precursor of HP. In contrast, the abundance of the alternative immature bifunctional hydroxylysinonorleucine (HLNL) cross-link was unchanged comparing wild-type and Tgm2 À/À mouse lungs, in a background of hyperoxia (Fig. 5E ). Collectively these data indicate that the impact of hyperoxia on collagen structure was mediated, at least in part, by TGM2.
TGM2 does not mediate the effects of hyperoxia on lung alveolar architecture
The role of TGM2 in hyperoxia-driven disturbances to the lung alveolar architecture was assessed by designbased stereology ( Fig. 6 and Table 1 ). Confirming previous reports [15, 36, 37] , exposure of newborn wildtype mice to 85% O 2 for the first 2 weeks of postnatal life caused alveolar simplification, which was evident by fewer alveoli, which were of a larger size ( Fig. 6B ) in comparison to the alveolar structure noted in 21% O 2 -exposed wild-type mice (Fig. 6A ). This trend was also noted comparing 21% O 2 -and 85% O 2 -exposed Tgm2 À/À mice.
The Sirius Red F 3B-stained lung tissue sections (Fig. 4) suggested an increased alveolar wall thickness in Tgm2 À/À mice compared with wild-type mice, all of which were maintained under normoxic conditions. The stereological analyses did indeed confirm that Tgm2 À/À mice exhibited increased arithmetic mean septal thickness (Fig. 6G) , and also, a reduced gasexchange surface area (Fig. 6F ). Comparing wild-type mouse lungs to Tgm2 À/À mouse lungs in a background of hyperoxia exposure, no differences were noted in gas-exchange surface density ( Fig. 6E ), gas-exchange surface area (Fig. 6F ), arithmetic mean septal thickness ( Fig. 6G ), mean linear intercept (MLI, a crude assessment of average diameter of an alveolus; Fig. 6H ), alveolar density ( Fig. 6I ), or total number of alveoli in the lungs (Fig. 6J ). Collectively, these data suggest that TGM2 played a role in normal lung alveolarization (under normoxic conditions), but did not play a role in the disturbances to the lung alveolar structure provoked by hyperoxia exposure in developing mouse lungs.
Cysteamine inhibits TGM2 activity in developing mouse lungs
Cysteamine is a widely employed competitive inhibitor of transglutaminase activity, and was successfully employed to inhibit transglutaminase activity in newborn mouse pups over the first 2 weeks of postnatal life (Fig. 7) . The utility of the cysteamine as a transglutaminase inhibitor was suggested by apparently decreased N e -(c-L-glutamyl)-L-lysine immunoreactivity in the lungs of cysteamine-versus solvent vehicle-treated mouse pups (Fig. 7A) , as well as apparently decreased transglutaminase activity on the TGM2-selective oligopeptide substrate (pepT26) in mouse lung cryosections from cysteamine-treated mice, in comparison to sections from solvent vehicle-treated mice (Fig. 7B) .
While cysteamine treatment of mouse pups blunted TGM2 catalytic activity in the lungs, cysteamine treatment increased steady-state Tgm2 mRNA levels in both 21% O 2 -(sevenfold) and 85% O 2 -exposed mice (three-fold) (Fig. 8A,B) . Cysteamine administration also decreased, albeit to a lesser degree, the steadystate mRNA levels of Tgm3, Tgm4, Tgm5 and Tgm6 (Fig. 8A,B ).
Cysteamine administration partially reverses the impact of hyperoxia on collagen structure in developing mouse lungs
The administration of cysteamine to developing mouse lungs did not have any apparent impact on collagen fibre structures visualized by Sirius Red F 3B staining of lung tissue sections, under normoxic or hyperoxic conditions (Fig. 9 ). However, quantitative analyses undertaken on collagen cross-links revealed a pronounced impact of cysteamine on collagen structures. Noteworthy was that the total number of collagen cross-links per unit collagen was decreased in the lungs from cysteamine-treated mouse pups versus lungs from solvent vehicle-treated mouse pups, in the background of hyperoxia exposure (Fig. 10B) , while the total collagen levels were unaffected comparing these two groups (Fig. 10A) . Specifically, the abundance of the mature, trifunctional HP cross-link was restored in 85% O 2 -exposed mouse pups to the same levels noted in 21% O 2 -exposed, solvent vehicle-treated mouse pups (Fig. 10C) , where HP levels were generally increased after hyperoxia exposure ( Fig. 5C and 9C ). Consistent with this observation, the abundance of the immature bifunctional DHLNL cross-link, which serves as the HP precursor, was also reduced by cysteamine treatment in the background of hyperoxia (Fig. 10D) . Additionally, an impact of cysteamine treatment on the abundance of the second immature bifunctional HLNL cross-link (Fig. 10E) was noted, although not on the ratio of DHLNL to HLNL (Fig. 10F) , in the background of hyperoxia. Collectively these data indicate that cysteamine administration could limit the impact of hyperoxia on collagen structure.
Cysteamine administration partially attenuated the impact of hyperoxia on selected elements of the lung alveolar architecture Consistent with the data presented in Fig. 6A ,B, exposure of solvent vehicle-injected wild-type mice to 85% O 2 for the first 2 weeks of postnatal life led to an increase in the size, and decrease in the number of alveoli in lung tissue sections (Fig. 11A,B) . Administration of cysteamine concomitant with hyperoxia exposure (Fig. 11D ) appeared to moderately limit the impact of hyperoxia exposure on the lung alveolar architecture (Fig. 11 and Table 2 ). Cysteamine administration resulted in an apparent decrease in alveolar size and increase in the number of alveoli (Fig. 11D) , compared with solvent vehicle-treated mice (Fig. 11B) , in the background of hyperoxia.
A designed-based stereological analysis revealed a moderate increase in gas-exchange surface density (Fig. 11E ) and a decrease in MLI (Fig. 11H ) in cysteamine-versus solvent vehicle-treated mice, in the background of hyperoxia. No impact of cysteamine administration on gas-exchange surface area (Fig. 11F) , arithmetic mean septal wall thickness (Fig. 11G ), alveolar density (Fig. 11I) or total number of alveoli in the lungs (Fig. 11J) was noted under normoxic or hyperoxic conditions, compared to solvent vehicle-treated mice. Thus, cysteamine administration had a limited protective influence on the impact of hyperoxia on the alveolar architecture in the developing mouse lung.
Discussion
Transglutaminases, in particular TGM2 [22] , are emerging as potentially important players in lung pathophysiology, where evidence exists implicating increased transglutaminase expression and activity in lung fibrosis [26, 27] , cystic fibrosis [28] and pulmonary hypertension [29] [30] [31] , chronic obstructive pulmonary disease (COPD) [38] , ventilator-induced lung injury [39] and allergic airway inflammation [32, 33] . The ability to inhibit the catalytic activity of transglutaminases has raised hopes that small-molecule transglutaminase inhibitors may form the basis of novel therapeutic or medical management strategies for these diseases, where particular attention has been paid to lung fibrosis [40] .
Several pathogenic roles have been ascribed to transglutaminases in lung pathophysiology. Among these are transglutaminase-mediated processes in lung fibroblasts, where increased TGM2 expression has been associated with increased fibronectin production, and TGM2 levels are reported to influence fibroblast adhesion and contractility [27] . Additionally, the aberrant (excessive) cross-linking of ECM structures is thought to generate ECM structures that are overstabilized, and thus, resistant to normal degradation pathways that facilitate the remodelling and removal of the ECM during organ development, as well as during repair after injury [4] . This idea, that an 'overstabilized' ECM plays a pathogenic role in lung disease has been addressed in pulmonary hypertension [41] , lung fibrosis [42] and arrested lung alveolarization associated with BPD [4, 13, 15, 17, 18] . ECM cross-linking is undertaken by different groups of enzymes which act in concert to promote protein cross-linking. For example, some lysine residues located in the teleopeptide region of collagen polypeptides are first hydroxylated by lysyl hydroxylase2, before these hydroxylated residues, as well as other nonhydroxylated residues, serve as substrates for any one of five lysyl oxidases. Lysyl oxidases then undertake the oxidative deamination of lysine and hydroxylysine side chains, thus creating peptidyl aaminoadipic-d-semialdehyde or peptidyl-dhydroxy-a-aminoadipic-d-semialdehyde residues, respectively, which may participate in spontaneous (nonenzymatic) condensation reactions to form covalent inter-and intramolecular cross-links [43] . Alternatively, a broad spectrum of proteins may be directly cross-linked by transglutaminases through the generation of an N e -(c-L-glutamyl)-L-lysine cross-link [20] . While many studies have reported increased expression of ECM cross-linking enzymes under pathological conditions, sadly, with the exception of BPD [15] and lung fibrosis [44, 45] , none of these studies have directly assessed the cross-link status of the ECM, but rather, altered ECM cross-linking is speculated at. It should be noted that in addition to impacting the ECM, TGM2 may also influence signal transduction, as a GTP-binding protein, such as in osteoclast differentiation [46] , where TGM2 can modulate NF-jB signalling, as it can in astrocytes [47] . These, together with other reports, such as those describing a role for TGM2 in encephalitogenic T-cell differentiation and inflammation [48] , highlight emerging non-ECM roles for TGM2, which need to be kept in mind when considering TGM2 as a causal player in pathology.
However, returning to the ECM, aberrant lung alveolarization associated with BPD is histopathologically characterized by pronounced disturbances to ECM structures. These disturbances include an abnormally increased abundance of collagen and a paucity of insoluble elastin, which together skew the ratio of collagen-to-elastin in favour of increased collagen, which is thought to reduce lung compliance, where the lung becomes 'more stiff' [15] . Furthermore, the structures of both collagen and elastin fibres in the developing septa are malformed. Collagen fibres in the lungs of infants that died with BPD have been described to be 'disorganized, tortuous and thickened' [9] , while in clinical BPD subjects, elastin fibres are described as being 'thickened, tortuous and irregularly distributed' [49] . Similarly, in animal models of BPD, the presence of 'abruptly terminating and tortuous' elastin fibres [50] , with a brush-like appearance [51] , have been noted. These abnormal collagen and elastin fibre structures have been attributed, at least in part, to the In situ detection of TGM2 catalytic activity in 5-lm sections prepared from the lungs of wildtype mouse pups exposed to 85% O 2 over the first 2weeks of postnatal life that concomitantly received either solvent vehicle (Veh.) or cysteamine (Cys.). TGM2 activity was revealed with peptide substrate pepT26, while a pepT26QN peptide that cannot be metabolized by TGM2 served as negative control. For both panels, cell nuclei were revealed by DAPI staining. Scale bar: 50 lm.
increased expression and activity of protein cross-linking enzymes noted in aberrantly developing lungs. The expression of several lysyl oxidases is reported to be elevated in both clinical and experimental BPD [10] [11] [12] [13] [14] [15] [16] 52] . Furthermore, expression of both the lysyl hydroxylase PLOD2 [17] , as well as TGM2 [18] , is increased in clinical and experimental BPD. Collectively, these reports have suggested ECM cross-linking enzymes as both candidate pathogenic mediators and potential therapeutic targets in BPD. Some ECM cross-linking enzymes are essential for normal lung development, for example, pharmacological inhibition of lysyl oxidases blocked lung alveolarization in developing rats [53, 54] , and genetic abrogation of Lox [55, 56] and Loxl1 [57] expression in mice led to perinatal death with malformation of the cardiopulmonary system, or to nonlethal alveolar simplification, respectively.
The role of lysyl oxidases as causal mediators of arrested alveolarization in the hyperoxia-based mouse model of BPD has been explored using the broadspectrum lysyl oxidase inhibitor BAPN [15] , given the perinatal lethality of Lox À/À mice. In that study, administration of BAPN effectively normalized lysyl oxidase activity in the lungs of hyperoxia-exposed mice, and this normalization of lysyl oxidase activity was accompanied by partial restoration of elastin cross-linking, which was assessed by the abundance of desmosine and isodesmosine cross-links. This improvement of elastin cross-linking was accompanied by improved elastin fibre structure in developing septa. However, the normalization of lysyl oxidase activity and improved septal elastin morphology was not accompanied by any improvement in the alveolar architecture of treated mice [15] . Thus, targeting lysyl oxidases to restore proper elastin fibre structure in developing lungs did not attenuate disturbances to lung alveolarization that were provoked by hyperoxia. Against this background, transglutaminases were addressed in the present study, given earlier reports of increased lung TGM2 expression in clinical and experimental BPD [18] . The data reported in the present study indicate that TGM2 does play a role in normal lung development, since Tgm2 À/À mice exhibited an increased septal thickness, and a decreased gas-exchange surface area. When employed in the hyperoxia-based mouse model of BPD, TGM2 was clearly implicated as a candidate mediator of the effects of hyperoxia on collagen structure. This was evident by the observation that in wild-type mice, hyperoxia provoked an increase in the abundance of the bifunctional DHLNL collagen cross-link and the trifunctional HP collagen cross-link in affected lungs; while in hyperoxia-exposed Tgm2 À/À mice, the abundance of DHLNL and HP cross-links was not impacted by hyperoxia. It is important to note that transglutaminases do not directly generate the DHLNL and HP cross-links, which are generated by lysyl oxidases. As such, hyperoxia must engage collagen processing pathways such that collagen fibre generation or maturation, including DHLNL and HP crosslinking, is disturbed. It is known that collagen V and collagen XI are substrates for transglutaminases, which cross-links collagens outside of the triple helical propeptide domains [58] . It might be speculated that this transglutaminase-mediated collagen cross-linking brings collagen polypeptides into sufficiently close proximity to allow the formation of the DHLNL and HP crosslinks. Thus, when TGM2 expression and activity are increased by hyperoxia, the formation of abnormally high levels of DHLNL and HP may be facilitated, and this facilitation is lost in Tgm2 À/À mice. It is important to note that, while no compensation of transglutaminase gene expression was noted in the lungs of wildtype versus Tgm2 À/À mice (Fig. 3B,C) ; compensatory changes in transglutaminase gene expression in Tgm2
mice have been noted in other tissues, such as the heart and liver [59] . Tissues from organs other than the lung were not examined in this study, and as such, a secondary effect of transglutaminase expression and activity on lung alveolarization cannot be ruled out in the present study.
Alternatively, a more indirect mechanism may be suggested, whereby transglutaminases enzymatically modify collagen interaction partners that are required for collagen maturation. These partners include, for example, microfibril-associated glycoprotein [60, 61] , and small leucine-rich repeat collagen chaperones such as biglycan and decorin [62] . Both of these explanations remain speculative. Although genetic abrogation of TGM2 expression in Tgm2 À/À mice was accompanied by partial restoration of collagen cross-linking in hyperoxia-exposed mice, loss of TGM2 expression did not protect mice from the deleterious impact of hyperoxia on lung alveolar development. By way of an alternative to genetic interference, a pharmacological approach was also adopted, using cysteamine, a broad-spectrum inhibitor of transglutaminases that is already approved for use in patients with cystinosis [63] . At the highest tolerated doses of cysteamine (50 mgÁkg ), transglutaminase activity could be appreciably inhibited in the lungs of treated mice. It is noteworthy that cysteamine, while regarded as an inhibitor of the catalytic activity of transglutaminases, also did impact the mRNA steady-state levels of multiple transglutaminase genes. The mechanisms of cysteamine effects on mRNA steady-state levels were not explored in this study. However, an impact of cysteamine on gene expression is not without precedent, where cysteamine has been documented to influence HIF1A (also called hypoxia-inducible factor-1, a subunit; HIF-1a) transcriptional responses, [64] by increasing HIF1A binding to DNA, and enhancing HIF1A interactions with other transcription factors, such as EGR1 (also called early growth response1).
While not explored mechanistically in this study, the possible modulation of transcriptional responded by cysteamine under conditions of altered oxygen tension is clearly noteworthy in hyperoxia-based models.
In terms of an effect on lung and ECM structure, cysteamine administration yielded broadly similar results to those obtained with the Tgm2 À/À mice.
Indeed, cysteamine administration reduced the abundance of DHLNL and HP cross-links in hyperoxiaexposed mice to normal DHLNL and HP abundance noted in mice breathing room air and treated with solvent vehicle alone. In addition, the abundance of a second immature bifunctional cross-link, HLNL, was also noted after cysteamine treatment. For both the Tgm2 À/À collagen cross-link data (Fig. 5 ) and the cysteamine collagen cross-link data (Fig. 10) , it is important to note that hyperoxia exposure aloneunder control conditions -did not increase the total number of collagen cross-links per unit collagen. However, a subgroup analysis of individual cross-links did reveal an impact of hyperoxia exposure, to varying degrees, on collagen cross-link abundance. The reason for this is that the cross-links form at different rates, have different stability (HLNL and DHLNL are unstable, while HP is stable) [65] and different abundance within collagen (e.g., from the data presented in Fig. 10B , the relative contribution of HP:DHLNL: HLNL to collagen in the vehicle-treated, hyperoxiaexposed mice was 0.039 : 1046 : 0.413 mol). In contrast to the impact of loss of TGM2 in Tgm2 À/À mice, cysteamine administration had no impact on septal thickness in wild-type mice breathing room air, where increased septal thickness had been noted in Tgm2 À/À mice. This might be due to only a partial loss of TGM2 activity after cysteamine administration, as opposed to a complete loss of TGM2 activity in the Tgm2 À/À mouse strain. These data may point to a role for TGM2 in the thinning of the alveolar walls as postnatal lung development proceeds. Also in contrast to the Tgm2 À/À mouse studies in the hyperoxia-based experimental animal model of BPD, cysteamine administration did impact the alveolar architecture in mice where alveolarization was blunted in response to hyperoxia. A very moderate improvement in gas-exchange surface density, as well as in MLI, which approximately reflects the mean diameter of the alveoli, was noted in the lungs of mice treated with cysteamine that were exposed to hyperoxia. As such, cysteamine appears to have some (but limited) utility in the protection of developing mouse lungs against the deleterious effects of concomitant hyperoxia exposure. Considered together with the parallel studies undertaken in the experimental BPD Table 2 . Where significant differences (P < 0.05) were evident within the vehicletreated groups (comparing 21% O 2 versus 85% O 2 exposure), or within the 85% O 2 -exposed groups (vehicle-treated versus cysteamine-treated), the P value is indicated.
model with Tgm2 À/À mice, these data suggest that protective effects of cysteamine on collagen structure in hyperoxia-exposed mice might be due to the inhibition of TGM2 activity, since broadly similar effects on collagen structure were obtained with Tgm2 À/À mice, and cysteamine-treated mice in the background of hyperoxia. However, different effects on alveolar architecture were noted comparing studies with Tgm2 À/À mice, and cysteamine-treated mice in the background of hyperoxia. Thus, the protective effects of cysteamine on the development of the alveolar architecture are most likely not due to inhibition of TGM2 activity, but rather, may be due to other, off-target effects of cysteamine. By way of conclusion, these studies suggest that a broad reconsideration of the utility of targeting ECM cross-linking systems to promote improved lung alveolarization is warranted. Loss of Tgm2 did impact normal lung development, but did not prevent hyperoxia-induced perturbations to lung development (although the abundance of collagen cross-links HP and DHLNL was normalized). As such, these data most likely rule our TGM2 as a candidate target in the context of aberrant alveolarization secondary to hyperoxia exposure. However, administration of the broad-spectrum (and nonspecific) transglutaminase inhibitor cysteamine did yield moderate protection, or reversion of lung alveolar architecture, which may suggest the utility of targeting other transglutaminases (other than TGM2), or non-transglutaminase targets of cysteamine.
The potential utility of targeting ECM remodelling enzymes during aberrant lung development has proved problematic in prior studies. For example, this concern has already been raised in studies targeting lysyl oxidases with BAPN, where BAPN administration to mice in an experimental BPD animal model could partially restore normal elastin structures to the lung, but this did not translate to improved lung alveolarization. A parallel observation is made in the present study with the Tgm2 À/À mice, where loss of TGM2 activity resulted in partially restored collagen structures in an experimental BPD animal model; however, this also did not translate to improved lung alveolarization. Indeed, the improved lung alveolarization noted with cysteamine administration was most likely not due to an impact on TGM2. These two independent studies suggest that a 'monotherapy' type of approach, where a single ECM cross-linking system is targeted, is unlikely to have translational potential. Rather, a combination of interventions that target multiple ECM cross-linking systems might represent a more viable approach. This idea is underscored by the observations that multiple different ECM cross-linking systems are simultaneously deregulated in aberrantly developing lungs. It would be most interesting to examine the effect of an intervention that simultaneously targets transglutaminases, lysyl oxidases and perhaps lysyl hydroxylases, on lung alveolarization in experimental BPD. Such an approach may -at the same time -promote improved collagen and elastin maturation, as well as that of other ECM structures, and thus presenting us with a more realistic outlook towards driving proper alveolar development in the background of hyperoxic injury. Values are presented as mean AE SD, n = 5 lungs per group. One-way ANOVA with Tukey's post hoc analysis.
Experimental procedures

Animal studies
All animal procedures were approved by the local authorities, the Regierungspr€ asidium Darmstadt (approval B2/ 1029). The generation of a knockout mouse strain carrying a targeted deletion of Tgm2 exons 6-8 on a C57BL/6J background has previously been described by the authors [66] . The genotype of Tgm +/À and Tgm2 À/À mice was confirmed by PCR (Fig. 1A) as described below. Furthermore, the loss of TGM2 protein expression was confirmed by immunoblot (Fig. 1B) as well as immunohistochemistry (Fig. 1C) . The immunoblot and immunohistochemistry protocols are described below. The broad-spectrum transglutaminase inhibitor cysteamine, a competitive amine inhibitor [67, 68] , was employed for in vivo pharmacological inhibition studies. Cysteamine (2-mercaptoethylamine) was employed because the pharmacokinetics are well described, given that cysteamine has been approved for use in patients with cystinosis [63] . Newborn mice were treated with cysteamine ( Both Tgm2 À/À mouse pups, as well as mouse pups treated with cysteamine, were exposed to normoxic (21% O 2 ) or hyperoxic (85% O 2 ) conditions, in a well-established experimental animal model of BPD [8, 70] . Nursing dams were rotated every 24 h between normoxia-and hyperoxiaexposed litters to minimize oxygen toxicity. Dams and pups were maintained on a 12-h/12-h light-dark cycle, and received food ad libitum.
Gene and protein expression, and protein and cross-link localization analysis
The correct genotype of Tgm2 À/À mice was confirmed by PCR analysis of gDNA isolated from tail biopsies undertaken as described previously [8] , using a combination of two forward primers, one of which ( 
Tgm2
À/À mice in Fig. 1A . Similarly, sex genotyping was undertaken as described in [71] which employs the Sry and Il3 loci to discriminate between male and female pups, exactly as described by the authors previously [8] . Steady-state mRNA levels were assessed in total RNA pools from mouse lungs, prepared as described previously [14, 15] , using the primers listed in Table 3 , to amplify mRNA encoding mouse transglutaminases (Tgm1-Tgm7), using Polr2a as a reference gene. The real-time RT-PCR amplifications and analyses were undertaken exactly as described previously [14, 15] . The real-time RT-PCR data are presented as the difference in cycle threshold (CT), DCT, which reflects the CT (Polr2a) À CT (Transglutaminase gene of interest) . Fold-change in mRNA abundance was given by fold-change = 2 |DDCT| .
Steady-state protein levels of TGM2 were documented by immunoblot, undertaken essentially as described previously [14, 15] , using rabbit anti-mouse TGM2 (abcam, catalogue number ab109200; 1 : 5000). Two different anti-TGM2 antibodies were evaluated, where the abcam antibody (ab109200) yielded a single, well-resolved band of the correct molecular mass (77 kDa) that was detected in wildtype but not Tgm2 À/À mouse lung extracts, along with a second ubiquitously expressed cross-reacting band at just under 50 kDa, which did not confound immunoblot interpretations (Fig. 2) . In contrast, a second antibody, goat antimouse/guinea pig TGM2 antibody (Millipore, 06-471; 1 : 5000; Waltham, MA, USA) performed very poorly, and could not be validated, yielding a mass of poorly resolved bands across the entire length of the lane, at multiple dilutions (Fig. 2) . Thus, the abcam antibody was employed throughout the present study, followed by horseradish peroxidase-conjugated goat anti-rabbit IgG (ThermoFisher, catalogue number 31460; 1 : 3000; Waltham, MA, USA). Loading equivalence was documented with a rabbit antimouse b-actin antibody (Cell Signaling Technology, catalogue number 4967; 1 : 1000; Danvers, MA, USA). Protein expression and localization were also documented by immunohistochemistry, essentially as described previously by the authors [72] . Briefly, 3-lm sections were cut from paraffin-embedded mouse lungs, which were then deparaffinized. For TGM2 detection, sections were stained using a rabbit anti-mouse TGM2 (abcam, catalogue number ab109200; 1 : 100) antibody, followed by an AlexaFluor Ò 488-conjugated goat anti-rabbit IgG (Invitrogen, catalogue number, A11008; 1 : 500). For detection of the TGM-generated N e -(c-L-glutamyl)-L-lysine cross-link, sections were prepared as described above, and stained with mouse monoclonal IgM antibody raised against chemically synthesized N e -(c-L-glutamyl)-L-lysine (abcam; catalogue number ab424; 1 : 50) followed by an DyLight Ò 550-conjugated goat anti-mouse IgM (abcam, catalogue number ab98675; 1 : 1000). Sections were simultaneously stained with 4 0 ,6-diamidino-2-phenylindole (0.5 mgÁmL À1 stock solution diluted 1 : 1000). Images were captured with a Leica DSC 360FX microscope.
Assessment of collagen protein and cross-links
The abundance of collagen, as well as the collagen crosslinks dihydroxylysinonorleucine (DHLNL), hydroxylysylpiridinoline (HP) and hydroxylysinonorleucine (HLNL) was determined exactly as described previously by the authors [15, 41, 65] . The nomenclature employed refers to the reduced variants of the intermediate collagen cross-links DHLNL and HLNL. The collagen structures present in developing septa were revealed by Sirius Red F 3B staining in 3-lm paraffin sections, exactly as described previously by the authors [13] .
In situ detection of transglutaminase activity in mouse lung sections
The protocol for the detection of transglutaminase activity in situ in frozen mouse tissue sections has been described in detail by the authors previously [73] . The protocol involves the enzymatic incorporation of a fluorescein isothiocyanate (FITC)-labelled peptide into acceptor substrates in the mouse tissues, in a reaction catalysed by transglutaminases. The selection of the peptide sequence allows for discrimination between TGM1 [74] , TGM2 [73] and TGM3 [75] activity, where the peptide HQSYVDPWNLDH (denoted pepT26) is a substrate for TGM2. As a negative control, a peptide in which the Gln 2 residue was replaced with an Asn residue (HNSYVDPWNLDH; denoted pepT26QN) was employed. For the reaction, 5-lm cryosections were air-dried and blocked by incubation in 1% (m/v) BSA in PBS for 30 min at room temperature. Sections were incubated for 60 min 100 mM Tris/Cl, 5 mM CaCl 2 , 1 mM dithiothreitol, pH 8.0, containing 2 lM FITC-labelled pepT26 or pepT26QN, at 37°C. Sections were washed (3 9 PBS), incubated in 25 mM EDTA in PBS (37°C, 5 min), washed (3 9 PBS), stained with DAPI (0.5 lgÁmL
À1
) and mounted in antifading solution. Fluorescence images were captured with a LSM5 PASCAL confocal laser-scanning microscope (Zeiss, Oberkochen, Germany).
Design-based stereology
The quantitative assessment of the lung architecture in developing mouse pups was based on the American Thoracic Society/European Respiratory Society recommendations for quantitative assessment of lung structure [76] . The methodological approach has been previously described in detail by the authors [8, 36, 72, 77, 78] . Mouse pup lungs were fixed through intratracheal instillation of 1.5% (m/v) paraformaldehyde, 1.5% (m/v) glutaraldehyde in 150 mM HEPES, pH 7.4, for 24 h at 4°C [79] , where fixative was instilled into lungs at a hydrostatic pressure of 20 cm H 2 O. Lung tissue blocks were then collected according to systematic uniform random sampling for stereological analysis [80, 81] . Total lung volume was assessed by Cavalieri's principle [82] . Lungs were embedded in agar in toto, cut into 3-mm slices, and treated with sodium cacodylate, osmium tetroxide and uranyl acetate, and embedded in glycol methacrylate (Technovit 7100, Heareus Kulzer, 64709003). Technovit blocks were sectioned at 2 lm, and stained with Richardson's stain. All slides were scanned using a NanoZoomer-XR C12000 Digital slide scanner (Hamamatsu). For the determination of total alveoli number, every first and third section of a consecutive series of sections was analysed. For all other parameters, every tenth section was analysed.
Analyses were made using the Visiopharm NewCast TM computer-assisted stereology system (VIS 4.5.3, Hoersholm, Denmark). Analyses included the determination of mean linear intercept (MLI), the arithmetic mean septal thickness, and gas-exchange surface area, as well as total alveoli number. The coefficient of error (CE), the coefficient of variation (CV) and the squared ratio between both (CE 2 /CV 2 ) were calculated for each stereological parameter, where a CE 2 /CV 2 <0.5 validated the precision of the measurements.
Statistics
Data are presented as mean AE SD. Differences between groups were assessed by one-way ANOVA with Tukey's post hoc test for multiple comparisons, while two-group comparisons were performed with an unpaired Student's ttest. P values ˂0.05 were regarded as significant. All statistical analyses were performed with GraphPad Prism 6.0. The presence of statistical outliers was tested by Grubbs' test, and statistical outliers were removed.
